PT-141 (Bremelanotide)
PT-141 (Bremelanotide)
Multi-buy savings: save 4% on 2+ items and 6% on 3+. Applied automatically in your cart.
Couldn't load pickup availability
- Same-day dispatch on orders before 2pm, Royal Mail Tracked
- Free UK shipping on orders over £100
- Certificate of Analysis with every order · Request CoA
- For in vitro laboratory research use only
Concentration calculator
For laboratory calculation only. Not for human or veterinary use.
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist, structurally derived from Melanotan II via hydrolysis of the lactam bridge. Unlike PDE5 inhibitors, PT-141 acts centrally via melanocortin receptors (primarily MC3R and MC4R) in the hypothalamus and limbic system, making it a uniquely CNS-targeted research tool for studying sexual function and appetite signalling pathways.
PT-141 has undergone extensive clinical investigation, culminating in FDA approval (as bremelanotide/Vyleesi) for hypoactive sexual desire disorder in premenopausal women. This clinical history provides a substantial pharmacokinetic and safety dataset useful for research context. Preclinical research explores MC3R/MC4R-mediated signalling, melanocortin CNS pathways, and peptide GPCR pharmacology.
Specifications
| CAS | 189691-06-3 |
|---|---|
| Formula | C50H68N14O10 |
| MW | 1025.2 g/mol |
| Purity | ≥99% HPLC |
| Format | Lyophilised powder |
| Storage | −20 °C |
Research areas
- MC3R / MC4R pharmacology
- Melanocortin CNS pathways
- Appetite & energy homeostasis
- GPCR research
- Reproductive endocrinology models
Selected literature
Research Use Only. Supplied strictly for in vitro laboratory research by qualified professionals. Not for human or veterinary administration. Not evaluated by the MHRA or FDA for therapeutic use. Researchers must comply with the Human Medicines Regulations 2012 and all applicable institutional guidelines. Peptide Biosciences accepts no liability for use outside a controlled research context.
Share
